IP Library › Granted Patent US 12,109,312
Granted Patent B2
US 12,109,312 · App. 17/341,785 · Granted Oct 8, 2024

Oral tablet for taste masking of active ingredients

Inventor: Helle Wittorff (Vejle Ost, DK)
Assignee: Fertin Pharma A/S
A61K9/2018A61K9/0056A61K9/2077A61K9/2095A61K31/522A61K9/2086
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,109,312
App. No.
17/341,785
Granted
Oct 8, 2024
Kind
B2
Abstract

An oral tablet for taste masking of active ingredients includes a population of particles and an active ingredient with off-note taste. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting at least partly in induced taste masking of the active ingredient upon mastication of the tablet.

Claims (18)

1. An oral direct compression tablet for taste masking of active ingredients, the tablet comprising a population of particles and an active ingredient with off-note taste, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles consisting essentially of pure non-DC sugar alcohol, the non-DC particles providing the direct compression tablet with a plurality of discrete non-DC areas formed by single non-DC particles or small groups of non-DC particles distributed between the DC particles, and the non-DC areas resulting at least partly in induced taste masking upon mastication of the tablet, wherein said active ingredient with off-note taste is selected from the group consisting of an active ingredient with bitter taste, an active ingredient with metallic taste, an active ingredient with astringent taste, an active ingredient with chalky taste, an active ingredient with salty taste, and combinations thereof.

2. An oral direct compression tablet for taste masking of active ingredients, the tablet comprising a population of particles and an active ingredient with off-note taste, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles consisting essentially of pure non-DC sugar alcohol, the non-DC particles providing the direct compression tablet with a plurality of discrete non-DC areas distributed between the DC particles, and the non-DC areas resulting at least partly in induced taste masking of the active ingredient upon mastication of the tablet, wherein said active ingredient with off-note taste is selected from the group consisting of an active ingredient with bitter taste, an active ingredient with metallic taste, an active ingredient with astringent taste, an active ingredient with chalky taste, an active ingredient with salty taste, and combinations thereof.

3. The tablet according to claim 2 , wherein the tablet comprises said non-DC sugar alcohol particles in an amount of at least 10% by weight of the tablet.

4. The tablet according to claim 2 , wherein at least 30% by weight of the non-DC sugar alcohol particles have a particles size above 500 μm.

5. The tablet according to claim 2 , wherein the tablet has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.3 and 0.7.

6. The tablet according to claim 2 , wherein the non-DC sugar alcohol particles are selected from non-DC particles of erythritol, maltitol, mannitol, xylitol, lactitol, isomalt, and combinations thereof.

7. The tablet according to claim 2 , wherein the tablet is a chewable tablet.

8. The tablet according to claim 2 , wherein said active ingredient with off-note taste is an analgesic selected from the group consisting of ibuprofen, acetaminophen, dextromethorphan, ampicillin, clarithromycin, metronidazole, loperamide, caffeine, sumatriptan, ascorbic acid, and combinations thereof.

9. The tablet according to claim 2 , wherein said active ingredient with off-note taste is an antihistamine selected from the group consisting of cimetidine, ranitidine, famotidine, nizatidine, desloratadine, and combinations thereof.

10. The tablet according to claim 2 , wherein said active ingredient with off-note taste is a gastrointestinal active selected from the group consisting of omeprazole, ondansetron, loperamide, simethicone, calcium carbonate, metoclopramide, cisapride, docusate, and combinations thereof.

11. The tablet according to claim 2 , wherein said active ingredient with off-note taste is selected from vitamins, minerals, supplements, and combinations thereof.

12. The tablet according to claim 2 , wherein said active ingredient with off-note taste is a hormone selected from the group consisting of progesterone, testosterone, melatonin, and combinations thereof.

13. The tablet according to claim 2 , wherein said active ingredient with off-note taste is a zinc salt selected from the group consisting of zinc acetate, zinc chloride, zinc gluconate, and combinations thereof.

14. The tablet according to claim 2 , wherein said population of particles is tableted into a first module and combined with a second population of particles that is tableted into a second module.

15. The tablet according to claim 2 , wherein said population of particles is tableted into a first module and combined with a second population of particles that is tableted into a second module, wherein the second population of particles includes particles comprising gum base.

16. The tablet according to claim 2 , wherein said population of particles is tableted into a first module together with particles comprising gum base and combined with a second population of particles that is tableted into a second module.

17. An oral tablet for taste masking of active ingredients, the tablet comprising a population of particles and an active ingredient with off-note taste, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles consisting essentially of pure non-DC sugar alcohol, the non-DC particles providing the tablet with a plurality of discrete non-DC areas distributed between the DC particles, and the non-DC areas resulting at least partly in induced taste masking of the active ingredient upon mastication of the tablet, wherein said active ingredient with off-note taste is selected from the group consisting of an active ingredient with bitter taste, an active ingredient with metallic taste, an active ingredient with astringent taste, an active ingredient with chalky taste, an active ingredient with salty taste, and combinations thereof.

18. The tablet according to claim 17 , wherein said active ingredient with off-note taste is selected from active ingredients for the throat selected from the group consisting of acetylcysteine, ambroxol, amylmetacresol, benzocaine, bisacodyl, bismuth subsalicylate, bromhexine, cetirizine, cetylpyridinium, chlorhexidine, dextromethorphan hydrobromide, 2,4-dichlorobenzyl alcohol, doxylamine succinate, eucalyptus oil, flurbiprofen, glycerin, hexylresorcinol, lidocaine, menthol, myrrh, paracetamol, pectin, peppermint oil, phenol, phenylephrine, povidone-iodine, pseudoephedrine, ranitidine, simethicone, sodium docusate, spearmint, zinc, and any combination thereof; active ingredients for the gastrointestinal tract selected from the group consisting of alginate, atenolol, aspirin (acetylsalicylic acid), ampicillin, aminosalicylates, anhydrous citric acid, bisacodyl, bismuth subsalicylate, bupropion, caffeine, calcium, calcium carbonate, cetirizine, cimetidine, cisapride, clarithromycin, desloratadine, dexlansoprazole, diphenhydramine HCl, diphenhydramine citrate, dimenhydrinate, docusate erythromycin, dopamine, esomeprazole, famotidine, fexofenadine HCl, guaifenesin, hydrotalcite, ibuprofen, ketoprofen, lactase enzyme, lansoprazole, loratadine, lorcaserin, loperamide, loperamide HCl, magnesium, magnesium carbonate, magnesium hydroxide, melatonin, methamphetamine HCl, metoclopramide, metronidazole, montelukast, mycostatin, naltrexone, naproxen, naproxen sodium, nizatidine, omeprazole, ondansetrone, orlistat, pantoprazole, paracetamol (acetaminophen), pectin, phentermine HCl, polypodium leucotomos, prednisolone, prednisone, progesterone, propranolol, propantheline bromide, pseudoephedrine HCl, phentermine, rabeprazole, ranitidine, roflumilast, scopoloamine butyl hydroxide, simethicone, sodium, sodium bicarbonate, sodium docusate, sumatriptan, testosterone, tetracycline, topiramate, vitamin A, vitamin B, vitamin B12, vitamin C (ascorbic acid), vitamin D, and vitamin E, vitamin K, and any combination thereof, and active ingredients for buccal absorption selected from the group consisting of atenolol, baclofene, caffeine, carvedilol, chlorpheniramine, chlorpheniramine maleate, fluticasone propionate, maleate, desmopressine, diltiazem hydrochloride, doxylamine succinate, mycostatin, nicotine, nifedipine, nitroglycerin, omeprazole, ondansetrone, oxymetazoline HCl, oxytocin, phenylephrine, piroxicam, prednisone, propranolol, salbutamol sulphate, scopoloamine butyl hydroxide, sumatriptan, triamcinolonacetonid, and any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2021
From: WITTORFF, HELLE
To: FERTIN PHARMA A/S
Reel/Frame 056671/0134 →
Continuity (2)
Continuation 15982510 · May 17, 2018
Related Publication 20210290547A1 · Sep 23, 2021
Cited By (2)
US 12,303,604 US 12,599,563